The plasma methylated SEPT9 is capable of detecting hepatocellular carcinoma and hepatic cirrhosis

The plasma methylated SEPT9 is capable of detecting hepatocellular carcinoma and hepatic cirrhosis: a case-cotrol study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000031547

Enrollment

Unknown

Registered

2020-04-04

Start date

2016-03-06

Completion date

Unknown

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic cirrhosis and hepatocellular carcinoma

Interventions

Gold Standard:Pathological diagnosis.

Index test:Plasma&#32

methylation&#32

SEPT9&#32

DNA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults over 18 years old with complete clinicopathological information and confirmed diagnosis of HCC, HC, or no evidence of disease (normal subjects) by imaging examination (including endoscopy, ultrasound, MRI, CT, etc.) and/or subsequent pathological examination.

Exclusion criteria

Exclusion criteria: Pregnant woman, history of any cancer, or history of therapy on any cancer.

Design outcomes

Primary

Measure	Time frame
SEN, SPE, ACC, AUC of ROC;PPV, NPV;+ LR, -LR;	—

Countries

China

Contacts

Public ContactHe Na

The First Affiliated Hospital of Xi'an Medical University

ylhena@163.com+86 18091275998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026